| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/09/2006 | WO2005094864A3 Treatment of hedgehog- and wnt-secreting tumors with inhibitors of lipoprotein particle biogenesis |
| 02/09/2006 | WO2005094358A3 Method of treating solid tumors and leukemias using combination therapy of vitamin d and anti-metabolic nucleoside analogs |
| 02/09/2006 | WO2005093425A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 58 (gpr58) |
| 02/09/2006 | WO2005093423A3 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
| 02/09/2006 | WO2005089365A3 Treatment and prevention of abnormal cellular proliferation |
| 02/09/2006 | WO2005086898A3 Inhibitors of histone deacetylase |
| 02/09/2006 | WO2005065291A3 Enteric coated aliphatic amine polymer bile acid sequestrants |
| 02/09/2006 | WO2005058238A3 Antimicrobial composition |
| 02/09/2006 | WO2005002586A8 Metabolite of quetiapine |
| 02/09/2006 | WO2004112771A8 Pharmaceutical compositions including an antihistamine and a stimulant and use thereof |
| 02/09/2006 | WO2004091494A3 Method for preparation of site-specific protein conjugates |
| 02/09/2006 | WO2003105761A3 Immunotoxin as a therapeutic agent and uses thereof |
| 02/09/2006 | WO2003090691A3 Method and compositions for identifying anti-hiv therapeutic compounds |
| 02/09/2006 | US20060031956 Nucleotide sequences for gene regulation and methods of use thereof |
| 02/09/2006 | US20060031946 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| 02/09/2006 | US20060030735 Adding a carbene-bearing or carbene equivalent-bearing compound across a double bond of an alkene compound to form a cyclopropyl ring, performing further chemical reactions on the additional functional groups incorporated |
| 02/09/2006 | US20060030717 5-(2-Cyano-5-pyrolyl)-2-indolinones: 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'yl)-1-methyl-1H-pyrrole-2-carbonitrile; contraceptives, hormone replacement therapy, dysmenorrhea, premenstrual syndrome, hormone-dependent neoplasia, uterine bleeding |
| 02/09/2006 | US20060030713 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
| 02/09/2006 | US20060030710 stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid; anti-HIV agent |
| 02/09/2006 | US20060030709 PNA monomer and precursor |
| 02/09/2006 | US20060030626 Method of treating autoimmune diseases |
| 02/09/2006 | US20060030625 Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters |
| 02/09/2006 | US20060030624 Alpha-Dicarbonyl compounds can be used to covalently modify and thereby inactivate prenylating enzymes such as protein farnesyltransferase and protein geranylgeranyltransferase; drug screening; antitumor agents; antiproliferative agents |
| 02/09/2006 | US20060030623 Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| 02/09/2006 | US20060030622 Compounds and methods for the treatment of urogenital disorders |
| 02/09/2006 | US20060030621 Preparation for external use on skin |
| 02/09/2006 | US20060030620 Method for treating and/or preventing ischemia/reperfusion injury |
| 02/09/2006 | US20060030619 Compositions and methods for chelation therapy |
| 02/09/2006 | US20060030618 Vanilloid receptor ligands and their use in treatments |
| 02/09/2006 | US20060030617 Compounds useful for the treatment of cancer, compositions thereof and methods therewith |
| 02/09/2006 | US20060030616 Anhydride modified cantharidin analogues useful in the treatment of cancer |
| 02/09/2006 | US20060030615 5-(2-Cyano-5-pyrolyl)-2-indolinones: 5-(4'-fluoro-2'-oxo-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'yl)-1-methyl-1H-pyrrole-2-carbonitrile; contraceptives, hormone replacement therapy, dysmenorrhea, premenstrual syndrome, hormone-dependent neoplasia, uterine bleeding |
| 02/09/2006 | US20060030614 dissolving in a solvent, precipitating crystal form by cooling the solution to about -20C |
| 02/09/2006 | US20060030613 Indole, indazole and indoline derivatives as CETP inhibitors |
| 02/09/2006 | US20060030612 2-Benzyl-3-(4-methoxyphenyl)-7-trifluoromethyl-2h-indazole; 3-[4-(2-benzyl-7-trifluoromethyl-2h-indazol-3-yl)-benzyl]-benzoic acid methyl ester, for example; useful in the treatment or inhibition of LXR (Liver X receptor) mediated diseases, e.g., cardiovascular diseases |
| 02/09/2006 | US20060030611 Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases |
| 02/09/2006 | US20060030610 Method of treating inflammatory diseases |
| 02/09/2006 | US20060030609 Oxazolidinones containing oxindoles as antibacterial agents |
| 02/09/2006 | US20060030608 Anti aromatase compounds pharmaceutical compositions and uses thereof |
| 02/09/2006 | US20060030607 Compounds for the reduction of excessive food intake |
| 02/09/2006 | US20060030606 Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| 02/09/2006 | US20060030605 Pharmaceutical compounds |
| 02/09/2006 | US20060030604 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 02/09/2006 | US20060030603 Novel aryl urea analogs and use thereof as antibacterial agents |
| 02/09/2006 | US20060030602 (S)-amlodipine malate |
| 02/09/2006 | US20060030601 Novel aminopyridine derivatives as mGluR5 antagonists |
| 02/09/2006 | US20060030600 Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| 02/09/2006 | US20060030599 Sulphonamide derivatives |
| 02/09/2006 | US20060030598 Thiazolyl inhibitors of Tec family tyrosine kinases |
| 02/09/2006 | US20060030597 Method of inhibiting angiogenesis |
| 02/09/2006 | US20060030596 NF-kappaB inhibitors |
| 02/09/2006 | US20060030595 Potassium channel inhibitors |
| 02/09/2006 | US20060030594 Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| 02/09/2006 | US20060030593 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/09/2006 | US20060030592 I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 02/09/2006 | US20060030591 Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
| 02/09/2006 | US20060030590 such as 2-Ethyl-5-fluoro-1-{1-[3-(4-fluorophenylsulfanyl)-propyl]-piperidin-4-yl}-1H-benzimidazole, used as modulators of chemokine receptor activity, for treatment and prevention of inflammatory diseases such as asthma, allergies and autoimmune diseases, such as rheumatoid arthritis and atherosclerosis |
| 02/09/2006 | US20060030589 N-(8H-Indeno[1,2-d]thiazol-2-yl)-benzamide; antidiabetic agent; adenosine 2B receptor antagonists; antidiabetic agent; diabetic retinopathy, asthma and diarrhea; antidepressant, hypotensive agent, Parkinson's disease |
| 02/09/2006 | US20060030588 Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| 02/09/2006 | US20060030587 Method of treating attention deficit disorders with d-threo methylphenidate |
| 02/09/2006 | US20060030586 Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation |
| 02/09/2006 | US20060030585 N-(2-[9-(8-Azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthen-3-yl]-phenyl)-acetamide; veterinary medicine; side effect reduction; analgesics; antagonist; antiinflammatory agents; psychhological/nervous system/urogenital disorders; drug abuse; diarrhea; gastritis; cardiovascular/respiratory disorders; kits |
| 02/09/2006 | US20060030584 2,8-Disubstituted naphthyridine derivatives |
| 02/09/2006 | US20060030583 to treat diseases mediated by kinase activity; for example: 2-diethylamino-5-[3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethyl-nicotinamide |
| 02/09/2006 | US20060030582 Administering tetrahydropyranyl cyclopentyl tetrahydropyridopyridine compound for therapy of inflammatory or disorder or disease |
| 02/09/2006 | US20060030581 Mannitol formulation for integrin receptor antagonist |
| 02/09/2006 | US20060030580 Contacting phenolic piperidines with opioid receptors; analgesics, anticonvulsants, antitussive agents; diarrhea, drug addiction |
| 02/09/2006 | US20060030579 Compounds for the treatment of proliverative processes |
| 02/09/2006 | US20060030578 Pharmaceutically active lipid based formulation of irinotecan |
| 02/09/2006 | US20060030577 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| 02/09/2006 | US20060030576 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| 02/09/2006 | US20060030575 Such as 4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-(3-amino-neopenta-1-carbamyl)]-aminoethylsulfonylamino- beta -alanine Hydrochloride; for therapy and prophylaxis of disease conditions that are associated with the biological activity of integrin receptors |
| 02/09/2006 | US20060030574 Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| 02/09/2006 | US20060030573 melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes |
| 02/09/2006 | US20060030572 Method of improved diuresis in individuals with impaired renal function |
| 02/09/2006 | US20060030571 Ecteinascidins |
| 02/09/2006 | US20060030570 Method for treating cryptorchidism |
| 02/09/2006 | US20060030569 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 02/09/2006 | US20060030568 Crystal modificaion of a N-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use |
| 02/09/2006 | US20060030566 Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| 02/09/2006 | US20060030565 Amide derivatives and nociceptin antagonists |
| 02/09/2006 | US20060030564 Inhibitors of Akt activity |
| 02/09/2006 | US20060030563 novel cannabimimetic pyrazole derivatives, that are less lipophilic and have shorter in vivo half-lives than known cannabimimetic pyrazole ligands, used to provide physiological effects for treating diseases, such as drug abuse, obesity, schizophrenia, epilepsy or cognition activators |
| 02/09/2006 | US20060030562 Use of an inhibitor of cathepsin-S-or-B to treat or prevent chronic obstructive pulmonary disease |
| 02/09/2006 | US20060030561 2-Benzyl-2-hydroxy-4-methyl-4-phenylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide for example; treating type II diabetes, obesity, hypertension, arteriosclerosis, or glaucoma |
| 02/09/2006 | US20060030560 Pyrimidine compounds |
| 02/09/2006 | US20060030559 Diazole derivatives |
| 02/09/2006 | US20060030558 use as pain relievers, gastrointestinal disorders; 2-Amino-3-aryl-1-[3-((hetero)aryl)piperidin-1-yl]-propan-1-one compounds |
| 02/09/2006 | US20060030557 Substituted pyridines having antiangiogenic activity |
| 02/09/2006 | US20060030556 Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency |
| 02/09/2006 | US20060030555 Imidazo(1,2-a)pyrazine compounds; cancers |
| 02/09/2006 | US20060030554 Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease |
| 02/09/2006 | US20060030553 Cell adhesion inhibitors |
| 02/09/2006 | US20060030552 such as fulvestrant |
| 02/09/2006 | US20060030551 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| 02/09/2006 | US20060030550 Pharmaceutical formulations |
| 02/09/2006 | US20060030549 Paricalcitol(zemplar) capsule controls secondary hyperparathyroidism (SHPT) in CKD stage 5 patients |
| 02/09/2006 | US20060030548 Methods of using ryanodine antagonists in treating neural injury |
| 02/09/2006 | US20060030547 Antineoplastic combinations |
| 02/09/2006 | US20060030546 antiallergen, viricide, herbicide, autoimmune diseases; screening procedure for the identification of enzymes GcpE and LytB inhibitor; 4-hydroxy-3-methyl-2-butenyl 1-pyrophosphate; precursor of higher isoprenoids in 2-methyl-D-erythritol pathway (MEP) |